Published in Lab Law Weekly, July 27th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Roche.
Report 1: A follow-up analysis tracking the outcome of patients with aggressive non-Hodgkin's lymphoma (NHL) who were treated with the innovative cancer therapy MabThera (rituximab) over seven years ago has revealed exciting results.
This analysis of the original pivotal phase III study has shown that over half (53%) of the patients treated with MabThera were still alive after seven years compared with just over a third (36%) of patients who had received...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.